Clinical Trial Update: A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adding demcizumab to carboplatin/pemetrexed in nonsquamous non-small cell lung cancer; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Nonsquamous Non-small Cell Neoplasm of Lung

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Demcizumab (demcizumab)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: OncoMed Pharmaceuticals, Inc. | Conditions: Nonsquamous Nonsmall Cell Neoplasm of Lung | Phase 2 | Status: COMPLETED | Results posted: 2018-08-20